Product Profiles: Targeted Cancer Therapies - Patient selection driving novel drug approvals

New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research
By: Fast Market Research, Inc.
 
 
Spread the Word
Listed Under

Tags:
* Drug
* Cancer
* Clinical

Industry:
* Medical

Location:
* Massachusetts - US

Oct. 25, 2012 - PRLog -- The rising incidence of cancer is continuing to drive intense R&D interest in oncology. Drug developers are shifting their attention towards the development of novel therapies for molecularly defined patient populations. The future will increasingly see the approval of targeted therapies for specific molecular aberrations and the incorporation of companion diagnostics in routine clinical practice.

Scope
* Includes targeted cancer therapy drug profiles and development overviews detailing the companies involved and the clinical data that led to approvals
* Includes SWOT analysis of each brand in the targeted cancer therapies class
* Overview of each brands positioning in its marketed indications relative to its competitors and in terms of its ability to meet unmet needs
* Analysis of the clinical and commercial attractiveness of the targeted cancer therapies

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/464844_product_profiles_target...
------------------------------------------------------------

Highlights

As the understanding of the molecular pathogenesis of cancer is improving, companies are increasingly selecting molecularly defined patient populations in the development of novel targeted therapies.

The rising incidence of cancer is continuing to drive high R&D activity in oncology. As a result, a number of new targeted therapies have entered the cancer market in the past two years. In 2012, five drugs have been approved by the US Food and Drug Administration (FDA).

In the period 2011-2012, a number of important developments took place in three of the 'Big Four' tumor types- breast, colorectal (CRC) and NSCLC.

Reasons to Get this Report
* Access detailed information about the drugs that make up the most lucrative class in the oncology market
* Understand the key factors that led to the success of some targeted cancer therapy brands and the issues which have hindered the uptake of others
* Understand how the targeted cancer therapies market will change in the future as developers target niche indications

Partial Table of Contents:

OVERVIEW

* Catalyst
* Summary

EXECUTIVE SUMMARY

* Strategic scoping and focus
* Datamonitor key findings
* Related reports

PRODUCT OVERVIEW

* Targeted cancer therapy brands

MARKETED PRODUCT PROFILES

* Adcetris (brentuximab vedotin; Seattle Genetics/Takeda)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Afinitor (everolimus; Novartis)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Arzerra (ofatumumab; Genmab/GlaxoSmithKline)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Avastin (bevacizumab; Genentech/Roche/Chugai)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Caprelsa (vandetanib; AstraZeneca)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Erivedge (vismodegib; Genentech/Roche/Chugai)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Gleevec (imatinib; Novartis)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Herceptin (trastuzumab; Roche/Chugai)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Inlyta (axitinib; Pfizer)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Iressa (gefitinib; AstraZeneca)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Istodax (romidepsin; Celgene)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Kyprolis (carfilzomib; Onyx)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Nexavar (sorafenib; Bayer Schering/Onyx)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Perjeta (pertuzumab; Genentech/Roche/Chugai)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Revlimid (lenalidomide; Celgene)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Sprycel (dasatinib; Bristol-Myers Squibb)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Sutent (sunitinib; Pfizer)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche/Chugai)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Tasigna (nilotinib; Novartis)

* Drug profile
*

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4648...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.
End
Email:***@fastmr.com Email Verified
Phone:1.800.844.8156
Zip:01267
Tags:Drug, Cancer, Clinical
Industry:Medical
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share